Cost-effectiveness of cardiac resynchronisation therapy

Heart

Volumn 98, Issue 24, 2012, Pages 1828-1836

  Boriani, Giuseppe ^a   Diemberger, Igor ^a   Biffi, Mauro ^a   Martignani, Cristian ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARDIOVASCULAR AGENT; CLOPIDOGREL; FIBRINOLYTIC AGENT; METOPROLOL; PERINDOPRIL;

CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL DECISION MAKING; CONSERVATIVE TREATMENT; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DETERIORATION; DISEASE CLASSIFICATION; DRUG ELUTING STENT; DRUG HYPERSENSITIVITY; EARLY DIAGNOSIS; EARLY INTERVENTION; ECG ABNORMALITY; EVIDENCE BASED MEDICINE; EXERCISE; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REVASCULARIZATION; HEART REHABILITATION; HEART TRANSPLANTATION; HOSPITALIZATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INTERMETHOD COMPARISON; LEFT VENTRICULAR ASSIST DEVICE; LONG TERM CARE; MEDICAL EDUCATION; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROPHYLAXIS; QRS COMPLEX; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; REVIEW; SUDDEN DEATH; SURVIVAL; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS;

CARDIAC RESYNCHRONIZATION THERAPY; COST-BENEFIT ANALYSIS; FRANCE; HEART FAILURE; HUMANS;

EID: 84870439016     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-301845     Document Type: Review

References (33)

1. Leclercq C, Cazeau S, Ritter P, et al. A pilot experience with permanent biventricular pacing to treat advanced heart failure. Am Heart J 2000;140:862-70.
2. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001;344:873-80. A landmark trial: the first randomised study on CRT in patients with moderate to severe heart failure. (Pubitemid 32224395)
3. Bax JJ, Gorcsan J 3rd. Echocardiography and noninvasive imaging in cardiac resynchronization therapy: results of the PROSPECT study in perspective. J Am Coll Cardiol 2009;53:1933-43. A very interesting viewpoint analysing the multiple factors influencing the response to CRT and the potential approaches targeted to improve patients'response.
4. Al-Majed NS, McAlister FA, Bakal JA, et al. Meta-analysis: cardiac resynchronization therapy for patients with less symptomatic heart failure. Ann Intern Med 2011;154:401-12. A systematic review and meta-analysis evaluating data from 25 randomised trials that enrolled more than 9000 patients, considering either the setting of NYHA class II-IV or class I-II heart failure.
5. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847.
6. Boriani G, Burri H, Mantovani LG, et al. Device therapy and hospital reimbursement practices across European countries: a heterogeneous scenario. Europace 2011;13(Suppl 2):ii59-65.
7. Boriani G, Biffi M, Russo M, et al. Primary prevention of sudden cardiac death: can we afford the cost of cardioverter-defibrillators? Data from the Search-MI Registry-Italian sub-study. Pacing Clin Electrophysiol 2006;29(Suppl 2):S29-34. (Pubitemid 44813757)
8. Maniadakis N, Vardas P, Mantovani LG, et al. Economic evaluation in cardiology. Europace 2011;13(Suppl 2):ii3-8.
9. Owens DK, Qaseem A, Chou R, et al. High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions. Ann Intern Med 2011;154:174-80. An interesting article addressing the topical issue of how to assess the value of healthcare interventions in terms of benefits, harms, costs and cost-effectiveness, a series of crucial steps for ensuring high value, high quality care.
10. Boriani G, Biffi M, Martignani C, et al. Expenditure and value for money: the challenge of implantable cardioverter defibrillators. QJM 2009;102:349-56.
11. Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004;7:518-28. (Pubitemid 39390832)
12. Appleby J, Devlin N, Parkin D. NICE's cost effectiveness threshold. BMJ 2007;335:358-9. (Pubitemid 47359304)
13. World Health Organization. http://www.who.int/choice/costs/CER- thresholds/en/index.html
14. Nichol G, Kaul P, Huszti E, et al. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. Ann Intern Med 2004;141:343-51.
15. Feldman AM, de Lissovoy G, Bristow MR, et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005;46:2311-21. An analysis derived from the COMPANION trial on cost-effectiveness of CRT-D and CRT-P in NYHA class III-IV heart failure patients. (Pubitemid 41785503)
16. Calvert MJ, Freemantle N, Yao G, et al. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur Heart J 2005;26:2681-8. A within-trial analysis of the CARE-HF study on cost-effectiveness of CRT-P in NYHA class III-IV heart failure patients. (Pubitemid 41746691)
17. Banz K, on behalf of the Eucomed CRT Steering Committee. Cardiac resynchronization therapy (CRT) in heart failure - a model to assess the economic value of this new medical technology. Value Health 2005;8:128-39.
18. Fattore G, Landolina M, Bontempi L, et al. Economic impact of cardiac resynchronization therapy in patients with heart failure. Available evidence and evaluation of the CRT-Eucomed model for analysis of cost-effectiveness. Ital Heart J Suppl 2005;6:796-803. (Pubitemid 44898627)
19. Caro JJ, Guo S, Ward A, et al. Modelling the economic and health consequences of cardiac resynchronization therapy in the UK. Curr Med Res Opin 2006;22:1171-9. (Pubitemid 44000737)
20. Yao G, Freemantle N, Calvert MJ, et al. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J 2007;28:42-51. An analysis based on CARE-HF data on cost-effectiveness of CRT-D and CRT-P in NYHA class III-IV heart failure patients, with a life-time horizon. (Pubitemid 46134956)
21. Fox M, Mealing S, Anderson R, et al. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model. Health Technol Assess 2007;11: iii-iv, ix-248. A systematic review and meta-analysis of data on CRT-P and CRT-D with development of a Markov model and estimate of cost-utility on the basis of resource use and costs associated with treating heart failure in the UK National Health Service.
22. Bentkover JD, Dorian P, Thibault B, et al. Economic analysis of a randomized trial of biventricular pacing in Canada. Pacing Clin Electrophysiol 2007;30:38-43. (Pubitemid 46114927)
23. Aidelsburger P, Grabein K, Klauss V, et al. Cost-effectiveness of cardiac resynchronization therapy in combination with an implantable cardioverter defibrillator (CRT-D) for the treatment of chronic heart failure from a German health care system perspective. Clin Res Cardiol 2008;97:89-97. (Pubitemid 351257992)
24. Blomström P, Ekman M, Lundqvist CB, et al. Cost effectiveness of cardiac resynchronization therapy in the Nordic region: an analysis based on the CARE-HF trial. Eur J Heart Fail 2008;10:869-77.
25. Bond M, Mealing S, Anderson R, et al. Is combined resynchronisation and implantable defibrillator therapy a cost-effective option for left ventricular dysfunction? Int J Cardiol 2009;137:206-15.
26. Callejo D, Guerra M, Hernández-Madrid A, et al. Economic assessment of cardiac resynchronization therapy. Rev Esp Cardiol 2010;63:1235-43.
27. Maniadakis N, Ekman M, Calvert MJ, et al. Cost effectiveness of cardiac resynchronization therapy in Greece: an analysis based on the CArdiac REsychronization in Heart Failure trial. Europace 2011;13:1597-603.
28. Bertoldi EG, Rohde LE, Zimerman LI, et al. Cost-effectiveness of cardiac resynchronization therapy in patients with heart failure: the perspective of a middle-income country's public health system. Int J Cardiol 2011 Jun 23. (Epub ahead of print).
29. Linde C, Mealing S, Hawkins N, et al. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction). Eur Heart J 2011;32:1631-9. The first study analysing the cost-effectiveness of CRT in patients with mildly symptomatic heart failure or with asymptomatic left ventricular dysfunction and previous heart failure symptoms.
30. Neyt M, Stroobandt S, Obyn C, et al. Cost-effectiveness of cardiac resynchronisation therapy for patients with moderate-to-severe heart failure: a lifetime Markov model. BMJ Open 2011;1:e000276.
31. Noyes K, Veazie P, Hall WJ, et al. Cost-effectiveness of cardiac resynchronization therapy in the MADIT-CRT trial. J Cardiovasc Electrophysiol 2012. doi: 10.1111/j.1540-8167.2012.02413 (Epub ahead of print).
32. Wells GA, Coyle D, Nichol G, et al. Cost-effectiveness of cardiac resynchronization therapy (CRT) for mild to moderate heart failure (abstract). Heart Rhythm 2012;9(Suppl):S71.
33. Lam SK, Owen A. Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials. BMJ 2007;335:925. An interesting approach: Bayesian network meta-analysis from a network of 12 studies (>8300 patients) on the efficacy of CRT-D over CRT-P.